Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;281(5):2429-2440.
doi: 10.1007/s00405-023-08417-8. Epub 2023 Dec 29.

Temporal trends of blood eosinophilia in severe uncontrolled CRSwNP treated with dupilumab: a real-life study

Eugenio De Corso  1 , Claudio Montuori  2 , Silvia Baroni  3   4 , Rodolfo F Mastrapasqua  5 , Davide P Porru  6 , Leandro M D'Auria  6 , Giuseppe D'Agostino  6 , Daniele Penazzi  6 , Gabriele De Maio  6 , Maria E Onori  3 , Francesca Sarlo  3 , Marco Corbo'  6 , Jacopo Galli  1   6
Affiliations

Temporal trends of blood eosinophilia in severe uncontrolled CRSwNP treated with dupilumab: a real-life study

Eugenio De Corso et al. Eur Arch Otorhinolaryngol. 2024 May.

Abstract

Purpose: Induced eosinophilia is commonly related to dupilumab treatment. We analysed the temporal trends of blood eosinophilia in patients with severe uncontrolled CRSwNP during the first year of treatment with dupilumab in real-life setting to evaluate its correlation with outcomes of response and adverse events (AEs).

Methods: Seventy-four patients with severe uncontrolled CRSwNP treated with dupilumab at our institution were enrolled. At each visit, we evaluated AEC, outcomes of response to treatment and AEs.

Results: A significant increase in AEC was observed since the first month with a peak at 3 months; at 12 months, the values returned comparable to those at baseline. A ≥ 50% increase of the baseline AEC with a value greater than 500 cells/mm3 was documented in 38/74 patients (Group A) regardless of the time of observation, whereas in 36/74 patients (Group B), no changes were observed. Analysing the blood eosinophilia trend over time in group A, we observed a temporary eosinophilia with early onset (within 6 months), persistent eosinophilia with early onset, and eosinophilia with late onset. No differences in terms of outcomes of response to treatment or AEs were found between Group A and Group B, or between patients who developed an AEC ≥ 1500 cells/mm3 or not.

Conclusion: In our series, we observed that an increase in AEC with different temporal trends may be observed in CRSwNP patients during the first year of treatment with dupilumab. In our series, eosinophilia is not correlated with a negative outcome of response to treatment or a risk of AEs.

Keywords: Biological therapy; Blood eosinophilia; Chronic rhinosinusitis with nasal polyps; Dupilumab; Hyper-eosinophilia.

PubMed Disclaimer

References

    1. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 58(Suppl 29):1–464. https://doi.org/10.4193/Rhin20.600 - DOI - PubMed
    1. Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P et al (2023) EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology 61(3):194–202. https://doi.org/10.4193/Rhin22.489 - DOI - PubMed
    1. De Corso E, Bellocchi G, De Benedetto M, Lombardo N, Macchi A, Malvezzi L et al (2022) Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology. Acta Otorhinolaryngol Ital 42(1):1–16. https://doi.org/10.14639/0392-100X-N1614 - DOI - PubMed
    1. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P et al (2016) Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis. JAMA 315(5):469 - DOI - PubMed
    1. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. The Lancet 394(10209):1638–1650. https://doi.org/10.1001/jama.2015.19330 - DOI

Substances

LinkOut - more resources